Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.60 |
| ▸ | JAK3 | P52333 | 5/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410129 | 0.93 | ALK (0.57) | ALKJAK3PTK2JAK2IGF1R | |
| SCHEMBL30433805 | 0.93 | ALK (0.57) | ALKJAK3PTK2JAK2IGF1R | |
| SCHEMBL20412675 | 0.93 | ALK (0.56) | ALKJAK3PTK2JAK2IGF1R | |
| SCHEMBL20429850 | 0.90 | ALK (0.54) | ALKJAK3PTK2JAK2IGF1R | |
| SCHEMBL18410133 | 0.90 | JAK3 (0.54) | ALKJAK3PTK2JAK2EGFR | |
| SCHEMBL18410126 | 0.90 | ALK (0.65) | ALKJAK3PTK2JAK2IGF1R | |
| SCHEMBL18410197 | 0.87 | ALK (0.60) | ALK | |
| SCHEMBL18410084 | 0.84 | ALK (0.47) | ALKJAK3JAK2IGF1R | |
| SCHEMBL24862245 | 0.81 | JAK3 (0.49) | ALKJAK3PTK2JAK2IGF1R | |
| SCHEMBL18410125 | 0.80 | ALK (0.51) | ALKJAK3PTK2JAK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-12-03 | — | — | US | disclosed |
| EP-3354653-B1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2019-09-04 | — | — | EP | disclosed |
| EP-3354653-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | Guangzhou Maxinovel Pharmaceuticals Co. Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| WO-2017012559-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | 广州再极医药科技有限公司 | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | FLT3, FGFR1, FGFR3 | ALK 39/4885JAK3 22/4885PTK2 198/4885 |
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | FLT3, FGFR1, FGFR3 | ALK 39/4885JAK3 22/4885PTK2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.